Oncogenic activation of tyrosine kinase like EGFR, PIK3CA, MET etc. are frequently observed in NSCLC and thereby offer opportunity for therapeutic targeting [25,26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.